OmniaBio
Michael Israels is currently the Chief Financial Officer at the Centre for Commercialization of Regenerative Medicine (CCRM) and also serves as the Director and CFO at OmniaBio. Additionally, Michael holds director positions at CCRM Australia and the Canadian Advanced Therapies Training Institute (CATTI) Inc. With a background in finance and accounting, Michael previously held roles such as CFO at ExCellThera Inc., Canadian Leader of Asset Management Advisory Services at Ernst & Young, and President at BEST Funds. Michael is a graduate of the Ivey Business School at Western University and holds designations from the Institute of Chartered Accountants of Ontario and the Canadian Institute of Chartered Business Valuators.
This person is not in any teams
OmniaBio
OmniaBio Inc., a subsidiary of CCRM, launched July 1, 2022. OmniaBio is a contract development and manufacturing organization (CDMO) conducting process development and producing gene-modified cells and viral vectors for Phase I clinical trials to commercial-scale manufacturing. OmniaBio is bringing life-saving cell and gene therapies to patients in Canada and around the world.